REGENXBIO Announces First Patient Dosed in Phase IIb/III Trial for Diabetic Retinopathy; Receives $100M

Key Facts

1First patient dosed in Phase IIb/III NAAVIGATE trial of surabgene lomparvovec (ABBV-RGX-314) for diabetic retinopathy using suprachoroidal delivery.

2Company to receive a $100 million milestone payment.

3New long-term data from diabetic retinopathy and wet AMD programs to be presented at ASRS 2026.

As gene therapy for eye diseases gains momentum, REGENXBIO has announced a key clinical milestone. According to reports, the first patient has been dosed in the Phase IIb/III NAAVIGATE trial of surabgene lomparvovec (ABBV-RGX-314) for diabetic retinopathy using suprachoroidal delivery. The milestone triggers a $100 million payment to the company. Additionally, long-term data from diabetic retinopathy and wet AMD programs will be presented at the American Society of Retina Specialists (ASRS) 2026 meeting.

RGNX shares closed at $10.48 on June 26, within a range of $9.94 to $10.78, per market data. The drug candidate is being developed in collaboration with AbbVie, underscoring the commercial potential. The $100 million milestone bolsters REGENXBIO's balance sheet as it advances pivotal-stage trials.

Currently trading near $10.48 (close June 26), RGNX finds support around $9.94 and resistance near $10.78. Key near-term catalysts include the ASRS 2026 data presentation and any updates from the AbbVie collaboration. The milestone payment provides additional financial flexibility for ongoing clinical programs.